The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes

BACKGROUND: The programmed cell death ligand 1 (PD-L1) plays a key role in glioma development. However, due to the specificity of glioma’s anatomical position, the role of its expression as a tumor biomarker is limited. It has been proven that the levels of soluble programmed death-ligand 1 (sPD-L1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xing-Chen, Wang, Liang-Liang, Zhu, Yu-Fang, Li, Yan-Dong, Nie, Shu-Lun, Yang, Jia, Liang, Hua, Weichselbaum, Ralph R., Yu, Jin-Ming, Hu, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668030/
https://www.ncbi.nlm.nih.gov/pubmed/33224142
http://dx.doi.org/10.3389/fimmu.2020.580335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668030/
https://www.ncbi.nlm.nih.gov/pubmed/33224142
http://dx.doi.org/10.3389/fimmu.2020.580335

Ejemplares similares